Is aripiprazole useful to refrain from cocaine use after detoxification (avoiding relapses)?

Addictive Disorders and their Treatment

Volumn 8, Issue 4, 2009, Pages 161-166

  Cassano, Giovanni B ^a   Lattanzi, Lorenzo ^a   Litta, Antonella ^a   Lombardi, Valentina ^a   Tatulli, Alessandro ^a   Benedetti, Alessandra ^a   Longobardi, Antonio ^a   Maremmani, Icro ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Aripiprazole; Bipolar disorder; Cocaine abuse addiction

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; COCAINE; DESIPRAMINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM CARBONATE; NIAPRAZINE; NORDAZEPAM; PAROXETINE; QUETIAPINE; SERTRALINE; VALPROIC ACID;

ADULT; ARTICLE; BEDTIME DOSAGE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; COCAINE DEPENDENCE; COMORBIDITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HUMAN; MALE; MOOD DISORDER; PANIC; PRIORITY JOURNAL; RELAPSE; SYMPTOM; WITHDRAWAL SYNDROME;

EID: 75149186540     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e318195001f     Document Type: Article

References (20)

1. Martin WR, Jasinski DR. Physiological parameters of morphine dependence in man, early abstinence, protracted abstinence. J Psychiatr Res. 1969;7: 9-17.
2. ISS. "Indagine IPSAD 2005" Italian Population Survey on Alcool and Drugs. Roma: ISS; 2005.
3. Rosenbaum JF, Fredman SJ. Pramipexole treatment for cocaine cravings. Am J Psychiatry. 1999;156: 1834.
4. Meini M, Capovani B, Sbrana A, et al. A pilot openlabel trial of ropinirole for cocaine dependence. Am J Addict. 2008;17:165-166.
5. Rothman RB, Blough BE, Baumann MH. Dual dopamine/ serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J. 2007;9: E1-E10.
6. Gawin F, Riordan C, Kleber H. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am J Drug Alcohol Abuse. 1985;11:193-197.
7. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol. 1996;6:243-251.
8. Roberts DC, Ranaldi R. Effect of dopaminergic drugs on cocaine reinforcement. Clin Neuropharmacol. 1995;18:S84-S95.
9. Loebl T, Angarita GA, Pachas GN, et al. A randomized, double-blind, placebo-controlled trial of long acting risperidone in cocaine-dependent men. J Clin Psychiatry. 2008;69:480-486.
10. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001;62:841-842.
11. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62:923-924.
12. Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry. 2007;61: 582-590.
13. Stoops WW, Lile JA, Glaser PE, et al. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend. 2006;84: 206-209.
14. Lile JA, Stoops WW, Vansickel AR, et al. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology. 2005;30: 2103-2114.
15. Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005; 66:756-760.
16. Raistrick DS, Bradshaw J, Tober G, et al. Development of the Leeds Dependence Questionnaire. Addiction. 1994; 89:563-572.
17. Maremmani I, Perugi G, Pacini M, et al. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord. 2006; 93:1-12.
18. Maremmani I. When a new drug promotes the integration of treatment modalities: suboxone and harm reduction. Heroin Addict Relat Clin Probl. 2008;10:5-12.
19. Maremmani I. Pharmacology and addiction: your definitive, cutting-edge guide. Addict Today. 2008: 28-31.
20. Le Foll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol Psychiatry. 2003;8:225-230.